

NOTIFICATION OF LATE FILING

Name of the Issuer: EALIXIR INC.

Check One: ☒ Annual Report ☐ Quarterly Report ☐ Interim Report

For Period Ended: 12/31/2023

Address of Principal Executive Office:

40 SW 13th St
Penthouse 1
Miami, FL 33132

Reason for Delay in Posting Financial Report: State below in reasonable detail why the Annual/Quarterly Report could not be filed within the prescribed time period.

The audit process for the financial statements for the year ended December 31, 2023 is ongoing and cannot be completed by the required filing date.

Anticipated Filing Date:

[Please note that the filing of this notification grants issuers 5 additional calendar days to post a Quarterly or Interim Report and 15 calendar days to post an Annual Report.]

April 15, 2024

Person to contact regarding this notification:

Date: 03/25/2024
Signature: /s/ Mark Corrao
Name: Mark Corrao
Title: CFO

Officer/Director Signature:

Date: 03/25/2024
Signature: /s/ Eleonora Ramondetti
Name: Eleonora Ramondetti
Title: CEO

Instructions to post Notification of Late Filing in www.OTCIQ.com:

1. Fill out this Notification of Late Filing form and convert the file to a PDF
2. Log in to www.OTCIQ.com and click "Add Financial Report" on the left hand navigation
3. Select Dissemination Date "Immediate"
4. Under Report Type, select "Notification of Late Filing"
5. Enter Period End Date corresponding to the quarter/fiscal year end date for which this Notice is being filed
6. Click "Browse" and select the PDF saved in step 1 above.
7. A preview of the document will appear next. Please make sure to review the entire document & scroll down to click the "**Submit**" button. Your Notification of Late Filing will appear within a few minutes on otcm Markets.com

Alternative Reporting companies on the Pink Current tier may utilize the Notification of Late Filing to receive the extension. The Notification must be submitted by the applicable reporting deadline to qualify for the extension.

OTCQB and OTCQX non-SEC reporting companies may also post this document to remain compliant with OTC reporting requirements.